Edward Fang

1.6k total citations
26 papers, 1.3k citations indexed

About

Edward Fang is a scholar working on Infectious Diseases, Pharmacology and Clinical Biochemistry. According to data from OpenAlex, Edward Fang has authored 26 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 9 papers in Pharmacology and 9 papers in Clinical Biochemistry. Recurrent topics in Edward Fang's work include Antimicrobial Resistance in Staphylococcus (18 papers), Bacterial Identification and Susceptibility Testing (8 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Edward Fang is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (18 papers), Bacterial Identification and Susceptibility Testing (8 papers) and Antibiotics Pharmacokinetics and Efficacy (7 papers). Edward Fang collaborates with scholars based in United States, Argentina and Canada. Edward Fang's co-authors include Philippe Prokocimer, Carisa De Anda, Anita Das, G. Ralph Corey, Purvi Mehra, Sonia L. Minassian, Gregory J. Moran, Thomas P. Lodise, Shawn D. Flanagan and Shawn Flanagan and has published in prestigious journals such as JAMA, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Edward Fang

26 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward Fang United States	14	862	482	346	295	231	26	1.3k
Yukihiro Hamada Japan	19	780 0.9×	305 0.6×	563 1.6×	90 0.3×	99 0.4×	102	1.4k
Toshimi Kimura Japan	17	731 0.8×	281 0.6×	613 1.8×	98 0.3×	81 0.4×	62	1.1k
David P. Benziger United States	19	442 0.5×	218 0.5×	439 1.3×	159 0.5×	150 0.6×	41	1.4k
Kazuro Ikawa Japan	23	565 0.7×	206 0.4×	1.2k 3.6×	85 0.3×	120 0.5×	127	1.9k
Kunihiko Morita Japan	17	274 0.3×	123 0.3×	267 0.8×	54 0.2×	83 0.4×	78	843
Nicholas J. Mercuro United States	11	469 0.5×	92 0.2×	142 0.4×	64 0.2×	90 0.4×	27	817
Robert Sauermann Austria	19	283 0.3×	168 0.3×	464 1.3×	93 0.3×	128 0.6×	43	1.1k
Norifumi Morikawa Japan	19	486 0.6×	160 0.3×	892 2.6×	23 0.1×	100 0.4×	101	1.4k
Edith Lackner Austria	19	167 0.2×	154 0.3×	442 1.3×	64 0.2×	142 0.6×	46	1.4k
William K. Lau United States	10	246 0.3×	158 0.3×	272 0.8×	50 0.2×	82 0.4×	12	1.3k

Countries citing papers authored by Edward Fang

Since Specialization

Citations

This map shows the geographic impact of Edward Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Fang more than expected).

Fields of papers citing papers by Edward Fang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Fang. The network helps show where Edward Fang may publish in the future.

Co-authorship network of co-authors of Edward Fang

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Fang. A scholar is included among the top collaborators of Edward Fang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Fang. Edward Fang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Bulitta, Jürgen B., Edward Fang, Martín E. Stryjewski, et al.. (2024). Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens. Antimicrobial Agents and Chemotherapy. 68(4). e0140023–e0140023. 3 indexed citations

2.

Fang, Edward, et al.. (2022). 1700. Efficacy and Safety in Subjects with Renal Impairment in Contezolid and Contezolid Acefosamil Phase 2 and Phase 3 Skin Infection Clinical Trials. Open Forum Infectious Diseases. 9(Supplement_2). 1 indexed citations

3.

Lee, Y.Y., Edward Fang, Yi-Ming Weng, & Sashikumar Ganapathy. (2017). Road traffic accidents in children: the ‘what’, ‘how’ and ‘why’. Singapore Medical Journal. 59(4). 210–216. 13 indexed citations

4.

Sandison, Taylor, Carisa De Anda, Edward Fang, Anita Das, & Philippe Prokocimer. (2017). Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials. Antimicrobial Agents and Chemotherapy. 61(5). 19 indexed citations

5.

Fang, Edward, et al.. (2016). Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers. American Journal of Therapeutics. 24(2). e227–e233. 16 indexed citations

6.

Fang, Edward, Philippe Prokocimer, Shawn D. Flanagan, et al.. (2016). Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections. The Brazilian Journal of Infectious Diseases. 20(2). 184–192. 13 indexed citations

7.

Flanagan, Shawn D., et al.. (2016). Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled study. International Journal of Antimicrobial Agents. 48(1). 33–40. 3 indexed citations

8.

Flanagan, Shawn D., Sonia L. Minassian, Thomas Marbury, et al.. (2014). Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment. Antimicrobial Agents and Chemotherapy. 58(11). 6471–6476. 49 indexed citations

9.

Moran, Gregory J., Edward Fang, G. Ralph Corey, et al.. (2014). Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Infectious Diseases. 14(8). 696–705. 241 indexed citations

10.

Shorr, Andrew F., Thomas P. Lodise, G. Ralph Corey, et al.. (2014). Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy. 59(2). 864–871. 120 indexed citations

11.

Ong, Voon, Shawn Flanagan, Edward Fang, et al.. (2014). Absorption, Distribution, Metabolism, and Excretion of the Novel Antibacterial Prodrug Tedizolid Phosphate. Drug Metabolism and Disposition. 42(8). 1275–1284. 62 indexed citations

12.

Lodise, Thomas P., Edward Fang, Sonia L. Minassian, & Philippe Prokocimer. (2014). Platelet Profile in Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid or Linezolid: Findings from the Phase 3 ESTABLISH Clinical Trials. Antimicrobial Agents and Chemotherapy. 58(12). 7198–7204. 57 indexed citations

13.

Tulkens, Paul M., et al.. (2013). Tedizolid Phosphate for the Management of Acute Bacterial Skin and Skin Structure Infections: Safety Summary. Clinical Infectious Diseases. 58(suppl 1). S51–S57. 39 indexed citations

14.

O'Riordan, W., et al.. (2013). Tedizolid Phosphate for the Management of Acute Bacterial Skin and Skin Structure Infections: Efficacy Summary. Clinical Infectious Diseases. 58(suppl 1). S43–S50. 13 indexed citations

15.

Prokocimer, Philippe, Carisa De Anda, Edward Fang, Purvi Mehra, & Anita Das. (2013). Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections. JAMA. 309(6). 559–559. 283 indexed citations

16.

Prokocimer, Philippe, Carisa De Anda, Edward Fang, Purvi Mehra, & Anita Das. (2013). Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections. 3 indexed citations

17.

Lin, Tony, Gregory Walker, Khaliq Kurji, et al.. (2013). Parainflammation associated with advanced glycation endproduct stimulation of RPE in vitro: Implications for age-related degenerative diseases of the eye. Cytokine. 62(3). 369–381. 55 indexed citations

18.

Fang, Edward, et al.. (2013). 916. Critical Care Medicine. 41. A229–A230. 2 indexed citations

19.

Flanagan, Shawn D., Ken Bartizal, Sonia L. Minassian, Edward Fang, & Philippe Prokocimer. (2013). In Vitro , In Vivo , and Clinical Studies of Tedizolid To Assess the Potential for Peripheral or Central Monoamine Oxidase Interactions. Antimicrobial Agents and Chemotherapy. 57(7). 3060–3066. 89 indexed citations

20.

Holland, Gary N., Edward Fang, Ben J. Glasgow, et al.. (1990). Necrotizing retinopathy after intraocular inoculation of murine cytomegalovirus in immunosuppressed adult mice.. PubMed. 31(11). 2326–34. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact